Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8U8KU)

Drug Name

NI006 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Amyloid transthyretin cardiomyopathy	5D00.20	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Transthyretin (TTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inotersen	DMJ93CT	Hereditary amyloidosis	5D00.2	Approved	[3]
ALN-TTRsc	DMFUOM7	Cardiomyopathy	BC43	Phase 3	[4]
Acoramidis	DMRAP4S	Transthyretin amyloid cardiomyopathy	5D00.20	Phase 3	[5]
NTLA-2001	DM1WDGE	Transthyretin amyloidosis	5D00	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04360434) A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Multicenter, Single and Multiple Ascending Dose Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy Followed by an Open-Label Extension. U.S.National Institutes of Health.
2	Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023 Jul 20;389(3):239-250.
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
5	Clinical pipeline report, company report or official report of AstraZeneca
6	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502.